System and method for treating a wound using ultrasonic debridement

Information

  • Patent Grant
  • 8075503
  • Patent Number
    8,075,503
  • Date Filed
    Tuesday, January 23, 2007
    18 years ago
  • Date Issued
    Tuesday, December 13, 2011
    13 years ago
Abstract
A wound treatment system includes a distribution manifold, a reduced pressure source, a fluid delivery source, and an ultrasonic energy transducer. Reduced pressure and fluid delivery may be applied to the wound through the distribution manifold. The ultrasonic energy transducer is configured to deliver ultrasonic energy to the wound to debride the wound. The ultrasonic energy transducer may be either a piezoelectric transducer or a surface acoustic wave device. The ultrasonic energy transducer may be placed adjacent to the distribution manifold to deliver ultrasonic energy directly to the wound or may be coupled to an acoustically-conducting membrane positioned between the distribution manifold and the wound.
Description
BACKGROUND OF THE INVENTION

A. Field of the Invention


The invention relates generally to wound treatment systems and methods, and more specifically to a system and method of treating a wound by combining ultrasonic debridement and reduced pressure therapy.


B. Description of Related Art


Wounds to the skin typically fall into two categories: chronic and acute. The natural healing mechanism in animals repairs acute wounds quickly by closing the wound, filling in lost tissue, and covering the wound with a new layer of skin. Those having observed wound healing in children often observe the healing of small acute wounds in a few days. Chronic wounds are often wounds in which the natural healing mechanisms have been impaired. Chronic wounds typically linger for extended periods of time and may never heal. Such wounds are often observed among the elderly or people suffering from diabetes. Another problem associated with wounds is infection. Infection is the invasion of a wound by pathogenic microorganisms or bacteria that grow within the wound, produce toxins, and subsequently injure the tissue surrounding the wound. To reduce the chance for infection of a wound, the wound is first cleaned to remove those microorganisms or bacteria that may have invaded the wound when it was created. Next, the wound typically is debrided or sterilized to remove nonviable or necrotic tissue and any microorganisms or bacteria resident within the wound. The third step in the treatment of a wound is to apply a dressing to cover the wound and promote its healing with the application of medication.


The debriding of a wound is often accomplished with mechanical surgical methods, referred to as sharps debridement. Specifically, the non-viable or necrotic tissue is cut from the wound and removed. Sometimes, surgical treatment of a wound will trigger the body's response to an acute wound and the wound will heal.


While the debridement process often involves cutting away tissue within the wound, recent efforts have involved the use of ultrasonic energy. A description of the use of ultrasonic energy and its use on skin appears in the following U.S. patents: Suroff, U.S. Pat. No. 4,040,414 (Ultrasonic Personal Care Instrument and Method); Beaty, et al., U.S. Pat. No. 5,312,329 (Piezo Ultrasonic and Electrosurgical Handpiece); Sakurai, et al., U.S. Pat. No. 5,391,144 (Ultrasonic Treatment Apparatus); Novak, et al., U.S. Pat. No. 6,171,265 (Handpiece for Use With a Multifunctional Operating Endoscopic Instrument); and in the following published PCT application: Babaev, WO 97/17933 (Method of Spraying A Surface Using Ultrasonic Radiation). Further descriptions are found in the following articles: King, et al., Burns, Vol. 22, No. 4, Pg. 307, (Debridement of Burn Wounds with a Surgical Ultrasonic Aspirator); Vanderburgh, et al., Gynecologic Oncology, Vol. 39, Pg. 103 (1990); (Debridement of Vaginal Radiation Ulcers Using the Surgical Ultrasonic Aspirator); and Herte, et al., Am. Society of Plastic and Reproductive Surgeons Prelim. Rpt. (November 1978); (Comparative Wound Healing in Animal Subjects Using the Cavitron Ultrasonic Surgical Aspirator vs. Conventional Surgical Instrument).


Further, in recently issued U.S. Pat. No. 6,916,296 to Soring, et al., entitled System for Antiseptic Surgery, a system using ultrasound was proposed for wound healing. Specifically, a device called a sonotrode is placed in a liquid within the wound. The sonotrode generates ultrasonic vibrations and cavitations in the liquid that leads to destruction of the bacteria cells. Specifically, the high level of energy released in the fluid kills the bacteria cells by rupturing their cell walls. While U.S. Pat. No. 6,916,296 reports a significant reduction in germ count in a wound, it is also taught that high levels of energy can be used for very short periods of time, or that lower levels of energy can be used for longer periods of time—up to several minutes.


In practice, the use of ultrasound to debride wounds involves relatively high amounts of ultrasonic energy typically applied in a focused manner to energize a relatively small area of a wound for a short period of time. The area over which ultrasonic energy is broadcast at any given time is typically less than about 5 cm2. Since the treatment is focused, the ultrasonic energy is typically only applied for less than about 60 seconds to any specific area.


Following debridement, wounds are dressed to cover the wound and promote healing. In recent years, it has been found that the application of reduced pressure to a wound promotes healing in many cases. This is particularly evident in chronic wounds, such as those that develop in elderly patients, but may also occur in any type of wound. Studies have also revealed that frequent irrigation of a wound helps promote healing by aiding in the removal of wound exudate, unwanted bioburden, and optionally, serving as an effective vehicle for the application & delivery of medication. Examples of wound treatment systems employing some of these techniques are found in the following U.S. patents: Zamierowski, U.S. Pat. No. 4,969,880 (Wound Dressing and Treatment Method); Zamierowski, U.S. Pat. No. 5,100,396 (Fluidic Connection System and Method); Zamierowski, U.S. Pat. No. 5,261,893 (Fastening System and Method); Zamierowski, U.S. Pat. No. 5,527,293 (Fastening System and Method); Argenta, et al., U.S. Pat. No. 5,636,643 (Wound Treatment Employing Reduced Pressure); Argenta, et al., U.S. Pat. No. 5,645,081 (Method of treating tissue damage and apparatus for same); Zamierowski, U.S. Pat. No. 6,071,267 (Medical Patient Fluid Management Interface System and Method); Vogel, et al., U.S. Pat. No. 6,135,116 (Method for Treating Ulcers); and Hunt, et al., U.S. Pat. No. 6,142,982 (Portable wound treatment apparatus).


While ultrasonic debridement has been taught as a way of initially clearing a wound of nonviable or necrotic tissue, the procedure has not gained acceptance as part of broad-based system for accelerating healing of a wound, in part due to the labor-intensive process involved with traditional ultrasonic debridement. A need currently exists for a system that utilizes ultrasonic energy at low energy levels over a prolonged period of time to debride a wound. For ease of use and improvement in performance, the application area over which the ultrasonic energy is applied should be relative large compared to existing procedures, which call for a more focused beam. Also needed is a system that employs a non-focused, low energy debridement procedure such as ultrasound, with reduced pressure therapy, and optionally, with a system providing fluid irrigation and removal of debrided tissue.


All of the patents, patent applications, and other publications referenced herein are incorporated by reference to the maximum extent allowable by law.


SUMMARY OF THE INVENTION

The problems presented by wound treatment systems tissue dressings are solved by the systems and methods of the present invention. In accordance with one embodiment of the present invention, a wound treatment system is provided that includes a distribution manifold, a reduced pressure source, and an ultrasonic energy transducer. The reduced pressure source is fluidly connected to the distribution manifold to deliver reduced pressure to a tissue site, and the ultrasonic energy transducer is positioned adjacent to the distribution manifold.


In accordance with another embodiment of the present invention, a wound treatment system for debriding and healing a wound site includes a distribution manifold, a reduced pressure source fluidly connected to the distribution manifold, an acoustically-conducting membrane, and an ultrasonic energy transducer. The acoustically-conducting membrane is positioned between the distribution manifold and the wound site, and the ultrasonic energy transducer is coupled to the membrane.


In still another embodiment of the present invention, a wound treatment system includes means for dressing a wound, means for reducing pressure at the wound, and means for debriding the wound.


In accordance with yet another embodiment of the present invention, an ultrasonic wound treatment system for treating a wound site includes an ultrasonic energy transducer configured to deliver ultrasonic energy to substantially all of the wound site at a power level less than about 1 W/cm2. The ultrasonic energy is delivered during a selected duration such that substantially all of the wound site is exposed to ultrasonic energy for at least ten minutes per day (10 min/day).


In yet another embodiment of the present invention, a wound treatment system includes a distribution manifold configured to be placed in fluid communication with a wound. A fluid source is fluidly connected to the distribution manifold and configured to deliver a fluid to the wound during a first selected duration. An ultrasonic energy transducer is configured to be placed in ultrasonic communication with and deliver ultrasonic energy to the wound during a second selected duration. A reduced pressure source is fluidly connected to the distribution manifold and configured to deliver a reduced pressure to the wound during a third selected duration.


In accordance with another embodiment of the present invention, a method for treating a wound includes simultaneously applying reduced pressure and ultrasonic energy to the wound to debride and heal the wound.


In still another embodiment of the present invention, a method for treating a wound includes delivering a fluid to the wound and allowing the fluid to dwell at the wound for a selected duration. Ultrasonic energy is applied to the wound during the selected duration, and a reduced pressure is applied to the wound following the selected duration to remove the fluid and any debrided tissue.


In another embodiment of the present invention, a multipurpose wound dressing includes a distribution manifold that is configured to distribute a reduced pressure to a wound site. An ultrasonic energy transducer is positioned adjacent to the distribution manifold to provide ultrasonic debridement to the wound site.


In yet another embodiment of the present invention, a multipurpose wound dressing includes a distribution manifold configured to distribute a reduced pressure to a wound site. An acoustically-conducting membrane is positioned on a tissue contact side of the distribution manifold and is configured to contact the wound site. An ultrasonic energy transducer is operatively coupled to the acoustically-conducting membrane.


Other objects, features, and advantages of the present invention will become apparent with reference to the drawings and detailed description that follow.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 illustrates a front cross-sectional view of a system for applying reduced pressure and ultrasonic energy to a wound or tissue site according to an embodiment of the present invention; and



FIG. 2 depicts a front cross-sectional view of a system for applying reduced pressure and ultrasonic energy to a wound or tissue site according to an embodiment of the present invention.





DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT

In the following detailed description of the preferred embodiments, reference is made to the accompanying drawings that form a part hereof, and in which is shown by way of illustration specific preferred embodiments in which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is understood that other embodiments may be utilized and that logical structural, mechanical, electrical, and chemical changes may be made without departing from the spirit or scope of the invention. To avoid detail not necessary to enable those skilled in the art to practice the invention, the description may omit certain information known to those skilled in the art. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the present invention is defined only by the appended claims.


Referring to FIGS. 1 and 2 a wound treatment system 10 according to an embodiment of the present invention includes a multipurpose wound dressing 11 having the capability of providing ultrasonic debridement to the wound, a reduced pressure source 12 to deliver reduced or subatmospheric pressure to the wound, and optionally, a fluid delivery source 14 to irrigate the wound with a fluid. A computer system 16 including a processor 17 and a user interface 18 may be provided to control all of the system functions of the reduced pressure therapy, debridement, and fluid delivery.


Referring more specifically to FIG. 1, the wound treatment system 10 is preferably used to debride and promote the healing of a wound site 100. Wound site 100 is surrounded by tissue 102. At least a portion of the wound site 100 includes a compromised layer of tissue 104, which may include a mixture of healthy, and non-viable live cells, dead cells, and varying amounts of contaminants such as micro-organisms and bacteria. Experimentation has revealed that this compromised layer of tissue may be as thick as 5 mm. While conventional treatment of the surface of the wound may remove dead tissue and bacteria on the surface of the wound, the bacteria beneath the surface are not removed and may continue to harbor infections. Debridement of the wound assists in the removal of this hidden bacteria.


The multipurpose wound dressing 11 includes a distribution manifold 20, an ultrasonic energy transducer 50, a tube 42 for fluidly communicating with the distribution manifold, and, optionally, a drape 30. The distribution manifold 20 is configured to be placed adjacent to the wound site 100. The distribution manifold 20 includes a plurality of flow channels or pathways to facilitate the distribution of reduced pressure or fluids to or from the wound site. In one embodiment the distribution manifold 20 is a porous foam and includes a plurality of interconnected cells or pores that act as flow channels. The porous foam may be a polyurethane, open-cell, reticulated foam such as GranuFoam manufactured by Kinetic Concepts, Inc. of San Antonio, Tex. If an open-cell foam is used, the porosity may vary, but is preferably about 400 to 600 microns.


The drape 30 is positioned over the distribution manifold 20 when an open wound site is treated to seal and isolate the wound site. If the wound site being treated is a subcutaneous or deep tissue wound site, drape 30 may not be necessary to maintain reduced pressure at the wound site. Drape 30 may be any biocompatible, flexible material. Drape 30 may be impermeable or semi-permeable to liquid, gas, or both depending upon a given application. A reduced pressure applicator 40 is placed under the drape 30 and over the distribution manifold 20. The tube 42 is fluidly connected at a distal end to the applicator 40 and is fluidly connected at a proximal end to the reduced pressure source 12, which may be a pump or a wall suction outlet. Near the reduced pressure source 12, the tube 42 is schematically represented as reduced pressure delivery tube 42a. The reduced pressure source is capable of supplying reduced pressure to the wound through the reduced pressure delivery tube 42a and distribution manifold 20. While the applicator 40 provides one means of transferring reduced pressure from the reduced pressure delivery tube 42a to distribution manifold 20, applicator 40 may be omitted if the reduced pressure delivery tube 42a is placed in direct fluid communication with distribution manifold 20.


A fluid delivery tube 42b may be provided to deliver a fluid to the wound and may similarly be fluidly connected to the distribution manifold by the applicator 40. The representation of tubes 42, 42a, and 42b in FIGS. 1 and 2 illustrate that a common applicator may be used for delivering reduced pressure and fluids to the distribution manifold 20. This may be accomplished by using the tube 42 for only one purpose at any time. More specifically, the tube 42 may be used to alternately deliver reduced pressure and fluids. In another embodiment, the tube 42 may be a dual lumen tube having a lumen for reduced pressure delivery and a lumen for fluid delivery. In still another embodiment (not illustrated), separate tubes may be used to fluidly communicate with the distribution manifold 20. If separate tubes are used, the use of an applicator 40 is optional.


The ultrasonic energy transducer 50 may include a frequency generator and an amplifier and is used to transmit ultrasonic energy to the wound site 100. The ultrasonic energy transducer may be a piezoelectric transducer or a surface wave acoustic device. In FIG. 1, the ultrasonic energy transducer 50 is placed between the applicator 40 and distribution manifold 20 to emit a low level of ultrasonic energy. The ultrasonic energy transducer 50 may be connected to one or both of the applicator 40 and the distribution manifold 20, or alternatively may be placed between the applicator 40 and distribution manifold 20 without physical connection to either. In one embodiment, the ultrasonic energy transducer 50 may be embedded within the distribution manifold 20.


The distribution manifold 20 acts as a transmission medium to relay ultrasonic energy to the wound site 100. When a reticulated foam is used, the transmission efficiency of the foam may be enhanced by using the fluid delivery source to infuse the foam with water, aqueous and sub-aqueous solutions, or gels. The presence of fluid within the foam improves the ability of the foam to transfer the ultrasonic energy. In this regard, the distribution manifold performs both the functions of a manifold and a transmission medium for ultrasonic energy. It should further be noted that gels or other transmission enhancing substances may be placed within or on the distribution manifold 20. For example, a gel may be placed between the distribution manifold 20 and the wound site 100 prior to the transmission of ultrasonic energy through the distribution manifold 20 to enhance energy transmission.


The amount of ultrasonic energy being applied to the wound by the ultrasonic energy transducer 50 is less than that of traditional ultrasonic debridement transducers. Preferably, if a high frequency (about 800 to 4000 kHz to) transducer is used, the power applied to the transducer is about 1.0 W/cm2, and more preferably about 0.5 W/cm2. If a low frequency (about 20 to 120 kHz to) transducer is used, the power applied to the transducer preferably is about 0.5 W/cm2, and more preferably about 0.1 W/cm2.


Referring to FIG. 2, the ultrasonic energy transducer 50 may be positioned remotely from the wound site 100 and may be operatively connected to an acoustically-conducting membrane 70 positioned between the distribution manifold 20 and the wound site 100. The membrane 70 may be connected to the distribution manifold 20, or alternatively may be placed without connection between the distribution manifold 20 and wound site 100 prior to administration of reduced pressure and ultrasonic therapies. In this embodiment, the low level of ultrasonic energy produced by the ultrasonic energy transducer 50 is transmitted across the membrane 70 and radiates into the compromised tissue layer 104. The proximity of the membrane 70 to the wound site 100 in some circumstances may improve the debridement performance of the wound treatment system 10. Since the ultrasonic energy is typically produced at low power, the ultrasonic energy transducer 50 may be positioned at or near the periphery of the wound site 100. Positioning of the membrane 70 between the distribution manifold 20 and the wound site 100 should not interfere with the capability of the distribution manifold to deliver reduced pressure or fluids to the wound site 100. In this regard, the membrane 70 is preferably formed from a naturally porous material, or alternatively is manufactured to include holes, pores, projections or other structural features that promote flow within, around, or through the membrane. The membrane may be made from a metallic foil, thin sheets of Lexan®, or any other material that is capable of conducting an ultrasonic wave.


In operation, the multipurpose dressing described herein combines reduced pressure therapy, ultrasonic debridement, and optional fluid delivery for debriding, cleaning, and healing the wound site. All of these functions may be integrated into a combined system that provides for the intermittent or continuous operation of each function individually or simultaneously, without changing the dressing between functions. Since the dressing is intended to remain in place for several days between changes, the ultrasonic energy transducer is optimized to provide debridement over long time periods at low power.


In one exemplary operational example, an irrigation or medicinal fluid is delivered by the fluid delivery source 14 to the distribution manifold during a first selected duration. Preferably, the first selected duration is about five (5) minutes. During this duration, the fluid is allowed to permeate the distribution manifold 20 and irrigate the wound site 100. During a second selected duration following the first selected duration, the fluid is allowed to dwell at the wound site and ultrasonic energy is transmitted to the wound site 100 by the ultrasonic energy transducer. The ultrasonic energy debrides the wound of nonviable and necrotic tissue. Preferably, the second selected duration is about fifteen minutes (15), or about three times the first selected duration. Following the second selected duration, transmission of ultrasonic energy is ceased, and reduced pressure is applied through the distribution manifold by the reduced pressure source. The reduced pressure removes the delivered fluid from the wound and distribution manifold, as well as wound exudate and debrided tissue. The application of reduced pressure continues for a third selected duration, which is preferably about forty (40) minutes, or about three times the second selected duration. The exemplary time durations described above may vary, and each of the procedures (i.e. fluid delivery, ultrasonic debridement, and reduced pressure therapy) may be performed independently of one another, or simultaneously with one or both of the other procedures.


It should be apparent from the foregoing that an invention having significant advantages has been provided. While the invention is shown in only a few of its forms, it is not just limited but is susceptible to various changes and modifications without departing from the spirit thereof.

Claims
  • 1. A method for treating a wound site comprising: providing a wound treatment system, the wound treatment system comprising: a distribution manifold comprising a porous foam having a plurality of flow channels for distributing reduced pressure,a reduced pressure source fluidly connected to the distribution manifold to deliver reduced pressure to the wound site,a reduced pressure applicator fluidly coupled to the distribution manifold and the reduced pressure source,a drape for positioning over the distribution manifold and at least a portion of the reduced pressure applicator, andan ultrasonic energy transducer configured to deliver ultrasonic energy to substantially all of the wound site at a power level less than about 1 W/cm2;disposing the porous foam of the distribution manifold adjacent to the wound site;fluidly coupling the reduced pressure applicator to the reduced pressure source;positioning the drape over the distribution manifold and at least a portion of the reduced pressure applicator;using the wound treatment system to debride the wound site and to provide reduced pressure therapy to the wound site without a dressing change, wherein the distribution manifold acts as a transmission medium to relay ultrasonic energy to the wound site and to transmit reduced pressure to the wound site; andwherein the step of using the wound treatment system to debride the wound site and to provide reduced pressure therapy to the wound site comprises: activating the ultrasonic energy transducer for a selective duration of at least fifteen (15) minutes whereby ultrasonic energy is provided to the wound site to debride the wound site, andactivating the reduced pressure source to provide reduced pressure to the wound site for at least forty (40) minutes to provide reduced pressure therapy.
  • 2. The method of claim 1, further comprising the step of providing an irrigation fluid to the distribution manifold for at least five minutes.
  • 3. The method of claim 1, wherein the ultrasonic energy transducer has a frequency between about 800 and 4000 kHz and wherein the power applied at the wound site is less than about 0.5 W/cm2.
  • 4. The method of claim 1, wherein the ultrasonic energy transducer is placed between the distribution manifold and the reduced pressure applicator.
  • 5. The method of claim 1, wherein the ultrasonic energy transducer is embedded in the distribution manifold.
CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 60/761,289, filed Jan. 23, 2006, which is hereby incorporated by reference.

US Referenced Citations (127)
Number Name Date Kind
1355846 Rannells Oct 1920 A
2547758 Keeling Apr 1951 A
2632443 Lesher Mar 1953 A
2682873 Evans et al. Jul 1954 A
2910763 Lauterbach Nov 1959 A
2969057 Simmons Jan 1961 A
3066672 Crosby, Jr. et al. Dec 1962 A
3367332 Groves Feb 1968 A
3520300 Flower, Jr. Jul 1970 A
3568675 Harvey Mar 1971 A
3648692 Wheeler Mar 1972 A
3682180 McFarlane Aug 1972 A
3826254 Mellor Jul 1974 A
4040414 Suroff Aug 1977 A
4080970 Miller Mar 1978 A
4096853 Weigand Jun 1978 A
4139004 Gonzalez, Jr. Feb 1979 A
4165748 Johnson Aug 1979 A
4184510 Murry et al. Jan 1980 A
4233969 Lock et al. Nov 1980 A
4245630 Lloyd et al. Jan 1981 A
4256109 Nichols Mar 1981 A
4261363 Russo Apr 1981 A
4275721 Olson Jun 1981 A
4284079 Adair Aug 1981 A
4297995 Golub Nov 1981 A
4333468 Geist Jun 1982 A
4373519 Errede et al. Feb 1983 A
4382441 Svedman May 1983 A
4392853 Muto Jul 1983 A
4392858 George et al. Jul 1983 A
4419097 Rowland Dec 1983 A
4465485 Kashmer et al. Aug 1984 A
4475909 Eisenberg Oct 1984 A
4480638 Schmid Nov 1984 A
4525166 Leclerc Jun 1985 A
4525374 Vaillancourt Jun 1985 A
4540412 Van Overloop Sep 1985 A
4543100 Brodsky Sep 1985 A
4548202 Duncan Oct 1985 A
4551139 Plaas et al. Nov 1985 A
4569348 Hasslinger Feb 1986 A
4605399 Weston et al. Aug 1986 A
4608041 Nielson Aug 1986 A
4640688 Hauser Feb 1987 A
4655754 Richmond et al. Apr 1987 A
4664662 Webster May 1987 A
4710165 McNeil et al. Dec 1987 A
4733659 Edenbaum et al. Mar 1988 A
4743232 Kruger May 1988 A
4758220 Sundblom et al. Jul 1988 A
4787888 Fox Nov 1988 A
4826494 Richmond et al. May 1989 A
4838883 Matsuura Jun 1989 A
4840187 Brazier Jun 1989 A
4863449 Therriault et al. Sep 1989 A
4872450 Austad Oct 1989 A
4878901 Sachse Nov 1989 A
4897081 Poirier et al. Jan 1990 A
4906233 Moriuchi et al. Mar 1990 A
4906240 Reed et al. Mar 1990 A
4919654 Kalt et al. Apr 1990 A
4941882 Ward et al. Jul 1990 A
4953565 Tachibana et al. Sep 1990 A
4969880 Zamierowski Nov 1990 A
4982730 Lewis, Jr. Jan 1991 A
4985019 Michelson Jan 1991 A
5016615 Driller et al. May 1991 A
5037397 Kalt et al. Aug 1991 A
5086170 Luheshi et al. Feb 1992 A
5092858 Benson et al. Mar 1992 A
5100396 Zamierowski Mar 1992 A
5134994 Say Aug 1992 A
5149331 Ferdman et al. Sep 1992 A
5167613 Karami et al. Dec 1992 A
5176663 Svedman et al. Jan 1993 A
5215522 Page et al. Jun 1993 A
5232453 Plass et al. Aug 1993 A
5261893 Zamierowski Nov 1993 A
5278100 Doan et al. Jan 1994 A
5279550 Habib et al. Jan 1994 A
5298015 Komatsuzaki et al. Mar 1994 A
5312329 Beaty et al. May 1994 A
5342376 Ruff Aug 1994 A
5344415 DeBusk et al. Sep 1994 A
5358494 Svedman Oct 1994 A
5391144 Sakurai et al. Feb 1995 A
5437622 Carion Aug 1995 A
5437651 Todd et al. Aug 1995 A
5524624 Tepper et al. Jun 1996 A
5527293 Zamierowski Jun 1996 A
5549584 Gross Aug 1996 A
5556375 Ewall Sep 1996 A
5607388 Ewall Mar 1997 A
5626554 Ryaby et al. May 1997 A
5636643 Argenta et al. Jun 1997 A
5645081 Argenta et al. Jul 1997 A
6071267 Zamierowski Jun 2000 A
6135116 Vogel et al. Oct 2000 A
6142982 Hunt et al. Nov 2000 A
6171265 Novak et al. Jan 2001 B1
6241747 Ruff Jun 2001 B1
6287316 Agarwal et al. Sep 2001 B1
6345623 Heaton et al. Feb 2002 B1
6488643 Tumey et al. Dec 2002 B1
6493568 Bell et al. Dec 2002 B1
6553998 Heaton et al. Apr 2003 B2
6814079 Heaton et al. Nov 2004 B2
6916296 Soring et al. Jul 2005 B2
7128719 Rosenberg Oct 2006 B2
7410469 Talish et al. Aug 2008 B1
7500956 Wilk Mar 2009 B1
7569742 Haggstrom Aug 2009 B2
20020055693 Thompson et al. May 2002 A1
20020077661 Saadat Jun 2002 A1
20020115951 Norstrem et al. Aug 2002 A1
20020115952 Johnson et al. Aug 2002 A1
20020120185 Johnson Aug 2002 A1
20020143286 Tumey Oct 2002 A1
20020156400 Babaev Oct 2002 A1
20030040687 Boynton et al. Feb 2003 A1
20030212351 Hissong et al. Nov 2003 A1
20040030304 Hunt et al. Feb 2004 A1
20040077977 Ella et al. Apr 2004 A1
20050020966 Soring et al. Jan 2005 A1
20060241533 Geller Oct 2006 A1
20090264807 Haggstrom Oct 2009 A1
Foreign Referenced Citations (37)
Number Date Country
550575 Aug 1982 AU
745271 Apr 1999 AU
755496 Feb 2002 AU
2005436 Jun 1990 CA
43 06 478 Sep 1994 DE
29504378 Sep 1995 DE
0100148 Feb 1984 EP
0117632 Sep 1984 EP
0161865 Nov 1985 EP
0358302 Mar 1990 EP
1 219 278 Jul 2002 EP
1018967 Aug 2004 EP
692578 Jun 1953 GB
1574066 Sep 1980 GB
2 195 255 Apr 1988 GB
2 197 789 Jun 1988 GB
2 220 357 Jan 1990 GB
2 235 877 Mar 1991 GB
2 333 965 Aug 1999 GB
2 329 127 Aug 2000 GB
4129536 Apr 1992 JP
2003-515424 May 2003 JP
2112571 Jun 1998 RU
2175539 Nov 2001 RU
2261692 Oct 2005 RU
71559 Apr 2002 SG
587941 Jan 1978 SU
1461466 Feb 1989 SU
WO 8002182 Oct 1980 WO
WO 8704626 Aug 1987 WO
WO 9010424 Sep 1990 WO
WO 9309727 May 1993 WO
WO 9420041 Sep 1994 WO
WO 9605873 Feb 1996 WO
WO 9717933 May 1997 WO
WO 9718007 May 1997 WO
WO 9913793 Mar 1999 WO
Related Publications (1)
Number Date Country
20070239078 A1 Oct 2007 US
Provisional Applications (1)
Number Date Country
60761289 Jan 2006 US